CordenPharma Hikes US Peptide Manufacturing Capacity
9th July 2020
CordenPharma is expanding the peptide manufacturing capacity at its GMP API facility in Boulder, Colorado, USA, to accommodate increased demand for peptide APIs, and to continue its overall growth strategy.
Matthieu Giraud, Director, Global Peptides, Lipids & Carbohydrates Platform, said: “With the addition of this extra-large 3’000 L SPPS vessel, our assembly-time, capacity and flexibility has been significantly increased, reinforcing CordenPharma Colorado as the current large-scale peptide manufacturing capacity leader.”
“This new asset gives us the ability to manufacture a complex long peptide with a 400 kg output per single batch. Our team in Colorado aims to utilize this new capacity to conduct validation campaigns designed to support customer projects with a global impact,” Giraud added.
With a 10’000 L SPPS (Solid-Phase Peptide Synthesis) vessel, and a 100 cm high-pressure reverse phase purification column, CordenPharma Colorado claims to be the largest worldwide peptide API producer and to lead the global peptide market.
The purification of the final peptide can be performed at any scale in columns ranging from 5 cm to 100 cm, the CDMO said. The Colorado site has a long track record in large-scale manufacturing, where all potencies, including picogram levels, can be reached.
With around 300 employees, CordenPharma has more than 130 years of cumulative experience across its global facility network in the US and Europe. This, it said, allows for a high-level of response to growing local demand at the country and community level, particularly during the ongoing Covid-19 pandemic.
For more information visit www.chemanager-online.com/en/